Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-3778 Bioavailability and DDI Study
NCT03032536Phase 1Terminated
- Sponsor
- Alios BioPharma
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AL-3778 in Chronic Hepatitis B (CHB) (7 arms), sponsored by Alios BioPharma. Primary endpoints: Maximum observed plasma concentration at Day 22, Area under the plasma concentration-time curve from time 0 to last measurable concentration at Day 22 and 3 more. Started Jan 2017; status: terminated.
02
Drugs
AL-3778
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03032536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032536.